Biopharma Firm Merges With Z Squared to Form Largest Publicly-Listed Dogecoin Miner

Coeptis and Z Squared Aim to Lead Dogecoin Mining Sector via Merger

Under the terms of the deal, Z Squared will become a wholly owned subsidiary of Coeptis (Nasdaq: COEP). Shareholders of Z Squared will receive equity in Coeptis in exchange for 9,000 U.S.-based dogecoin (DOGE) mining machines.

The transaction, approved by both boards, requires regulatory clearances, Nasdaq listing compliance, and shareholder approval. Closure is anticipated in Q3 2025, with the combined entity rebranding as Z Squared, Inc. and trading on Nasdaq.

Z Squared executives David Halabu and Michelle Burke will lead the merged company as CEO and COO, respectively. Coeptis CEO Dave Mehalick will depart the board post-closure. Halabu, founder of Group 10 Capital Management, emphasized the merger’s goal to offer investors focused exposure to dogecoin’s $27 billion market cap.

The new company will prioritize dogecoin mining, leveraging proof-of-work blockchain rewards. Mehalick noted shareholders could engage in dogecoin markets while retaining ties to spun-off biopharma operations, which will operate independently post-merger.

Coeptis’ biopharmaceutical divisions, developing cell therapies for cancer and infectious diseases, will continue under the spun-off entity. Its technology division, featuring AI and automation tools, remains with the merged company.

Z Squared, specializing in DOGE and litecoin (LTC) mining, aims to capitalize on the altcoin mining sector. Additional transaction details will be filed with the U.S. Securities and Exchange Commission (SEC), including proxy materials for shareholder review. Investors are directed to SEC filings for specifics on leadership interests and merger terms.